Catalent, which belongs to the Zacks Medical - Drugs industry, posted revenues of $623 million for the quarter ended December 2018, surpassing the Zacks Consensus Estimate by 3.11%. This compares to year-ago revenues of $606.30 million. The company has topped consensus revenue estimates two times over the last four quarters.